검색어: jikkompeti (몰타어 - 영어)

l- anqas jikkompeti man- nucleoside triphosphatase.
the activity of nevirapine does not compete with template or nucleoside triphosphates.

is-settur tas-sajd jikkompeti ma’ flotot tas-sajd tal-ue.
fishing sector competing with eu fleets.

cetrorelix jikkompeti ma’ l- għaqda ta’ lhrh endoġeni għal dawn ir-riċetturi.
cetrorelix competes with the binding of endogenous lhrh to these receptors.

ir-rifjut jirrigwarda prodott jew servizz li huwa oġġetivament meħtieġ biex ikun jista’ jikkompeti effettivament fuq suq downstream;
the refusal relates to a product or service that is objectively necessary to be able to compete effectively on a downstream market;

l-iżvilupp ta’ dan is-settur huwa kruċjali għar-reġjun euro-med sabiex jikkompeti globalment.
development of this sector is crucial for the euro-med region to compete globally.

it-t2s mhuwiex impriża kummerċjali u mhuwiex intiż biex jikkompeti ma » csds jew ma » xi parteċipant ieħor fis-suq.
t2s is not a commercial venture and it is not intended to compete with csds or any other market participant.

fl-istess ħin jassigura suq ekwu fejn il-kummerċ ewropew jista’ jikkompeti b’mod effettiv u bi prodotti innovattivi.
at the same time it ensures a fair market place where european business can compete effectively and with innovative products.

billi jikkompeti mas- sottostrat naturali deoxyguanosine tp, entecavir tp jaħdem billi ixejjen it- tlett attivitajiet tal- polymerase virali:
by competing with the natural substrate deoxyguanosine tp, entecavir-tp functionally inhibits the 3 activities of the viral polymerase:

iżda, jista’ jkun diffiċli għall-qasam tar-riċerka fuq perijodu ta’ żmien twil li jikkompeti għall-fondi.
however, it may be difficult for really long-term research to compete for funding.

levodopa jikkompeti ma’ ċerti amino aċidi għat-trasport, għalhekk ċerti ikliet bi proteina għolja jistgħu jdgħajfu l-assorbiment ta’ levodopa.
levodopa competes with certain amino acids for transport, therefore high protein meals may impair the absorption of levodopa.

l-użu simultanju ta’ sustanzi oħra b’livell għoli ta’ twaħħil mal-proteini jista’ jikkompeti mat-twaħħil ta’ masitinib u b’hekk jikkawża effetti avversi.
concurrent use of other substances with a high degree of protein binding may compete with masitinib binding and thus cause adverse effects.